SNOA — Sonoma Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $4.88m
- -$0.27m
- $14.29m
- 48
- 63
- 70
- 63
Annual cashflow statement for Sonoma Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.95 | -5.09 | -5.15 | -4.83 | -3.46 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -1.04 | -1.87 | 0.602 | 0.677 | 0.398 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.38 | 3.35 | -1.69 | 1.69 | 2.48 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.38 | -4.25 | -6.15 | -2.4 | -0.088 |
| Capital Expenditures | -0.179 | -0.137 | -0.269 | -0.017 | -0.08 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.567 | 0.038 | 0.011 | 0.015 | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.388 | -0.099 | -0.258 | -0.002 | -0.08 |
| Financing Cash Flow Items | — | — | — | — | -0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.31 | 7.4 | 2.49 | 1.68 | 3.03 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.529 | 3.18 | -3.58 | -0.692 | 2.25 |